Platelet Deposition at Angioplasty Sites and Platelet Survival Time After PTA in lliac and Femoral Arteries: Investigations with Indium-111-Oxine Labelled Platelets in Patients with ASA (1.0 g/Day)-Therapy

Summary

In this study we have assessed the deposition of 111-In-oxine-labelled platelets - using a dual radiotracer method - at angioplasty sites of the lower extremities in 20 patients (14 male, 6 female; median age: 60 years) with ASA (1.0 g/day)-therapy. The platelet survival time (PST) - using the multiple hit model -was evaluated before and after percutaneous transluminal angio-plasry, and we also measured the plasma levels of β-thrombo-globulin (β TG) and platelet fuetui 4 (PF 4) before and after PTA.

Before PTA, scintigraphy was positive in only one patient, while 24 hours after PTA a positive scintigraphic result was observed in 16/20 patients. The median target/non target-ratio was 1.0 (0.66-1.3) before PTA, and this ratio increased significantly (p <0.0005) to 1.53 (1.0-3.3) after PTA.

The median PST decreased significantly (185.0 hours before PTA → 145.2 hours after PTA; p <0.001), while the median platelet turnover increased from 34,000/μl/day to 47,900/μl/day(p<0.01).

The median plasma levels of the platelet specific proteins increased significantly immediately after PTA (p <0.001), but one day later they were not significantly different from the pretreatment values.

The quantitative methods used in this study seem a valuable tool to evaluate the effects of different therapeutical - especially antiplatelet - interventions after PTA in humans, thus helping to find the best antithrombotic regimen for this widely used therapeutical procedure.

Keywords

Transluminal angioplasty - Platelet scintigraphy - Platelet survival time - Acetylsalicylic acid

• References

• 1 Block PC, Myler RK, Stertzer S, Fallon JT. Morphology after transluminal angioplasty in human beings. N Engl J Med 1981; 205: 382-392
• 2 Richter E-I, Zeitler E. Percutaneous transluminal angioplasty: adjunct drug therapy. In: Dotter CT, Griintzig AR, Schoop W, Zeitler E. (eds) Percutaneous Transluminal Angioplasty. Springer; Berlin-Heidelberg-New York: 1983: 84-90
• 3 Rusnak B, Castaneda-Zuniga WR, Amplatz KA. The use of anticoagulants in transluminal angioplasty. In: Castaneda-Zuniga WR. (ed). Transluminal angioplasty. Thieme - Stratton Inc.; 1983: 28-30
• 4 Cunningham DA, Kumar B, Siegel BA, Gilula LA, Totty WG, Welch MJ. Aspirin inhibition of platelet deposition at angioplasty sites: demonstration by platelet scintigraphy. Radiology 1984; 151: 487-490
• 5 Powers WJ, Hopkins KT, Welch MJ. Validation of the dual radiotracer method for quantitative In-111 platelet scintigraphy. Thromb Res 1984; 34: 135-145
• 6 Harker LA. Platelet survival time: its measurement and use. Prog Hemostasis Thromb 1978; 4: 321-347
• 7 Harker LA, Slichter SJ, Sauvage LR. Platelet consumption by arterial prostheses: The effects of endothelialization and pharmacologic inhibition of platelet function. Ann Surg 1977; 186: 594-601
• 8 Ludlam CA. Beta-thromboglobulin, present state of the art. In: Hardeman MR, Najean Y. (eds) Blood cells in nuclear medicine, part I. Martinus Nijhoff Publishers; 1984: 291-299
• 9 Thakur ML, Walsh L, Malech HL, Gottschalk A. Indium-111-labelled human platelets: improved method, efficacy and evaluation. J Nucl Med 1981; 22: 381-385
• 10 International Committee for Standardization in Haematology. Recommended methods for radioisotope platelet survival studies. Blood. 1977 50. 1137-1144
• 11 Marker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48: 963-974
• 12 Schwartz KD, Kruger M. Improvement in labelling erythrocytes with ^99mTc-pertechnetate. J. Nucl. Med. 1977; 12: 323-324
• 13 Packham MA, Mustard JF. The role of platelets in the development and complications of atherosclerosis. Semin Hematol 1986; 23: 8-26
• 14 Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976; 295: 369-377
• 15 Ross R, Vogel A. The platelet-derived growth factor. Cell 1978; 14: 203-210
• 16 Castaneda-Zuniga WR, Sibley R, Amplatz K. The pathologic basis of angioplasty. Angiology 1985; 35: 195-205
• 17 Pasternak RC, Baughman KL, Fallon JT, Block PC. Scanning electron microscopy after coronary transluminal angioplasty of normal canine coronary arteries. Am J Cardiol 1980; 45: 591-598
• 18 Steele PM, Chesebro JH, Stanson AW, Holmes Jr DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112
• 19 Finklestein S, Miller A, Callahan RJ, Fallon JT, Godley F, Feldman BL, Hinton RC, Roberts AB, Strauss HW, Lees RS. Imaging of acute arterial injury with 111-In-labelled platelets: a comparison with scanning electron micrographs. Radiology 1982; 145: 155-159
• 20 Groves HM, Kinlough-Rathbone RL, Richardson M, Moore S, Mustard JF. Platelet interaction with damaged rabbit aorta. Lab Invest 1979; 40: 194-200
• 21 Eldor A, Falcone DJ, Hajjar DP, Minick CR, Weksler BB. Recovery of prostacyclin production by de-endothelialized rabbit aorta. J Clin Invest 1981; 67: 735-741
• 22 Gailer H, Griintzig AR, Zeitler E. Late results of the percutaneous transluminal angioplasty of iliac and femoropopliteal obstructive lesions - a cooperative study. In: Dotter CT, Griintzig AR, Schoop W, Zeitler E. (eds) Percutaneous Transluminal Angioplasty. Springer; Berlin - Heidelberg - New York: 1983: 215-218
• 23 Minar E, Ahmadi RA, Ehringer H, Marosi L, Czembirek H, Konecny U. Percutaneous transluminal angioplasty for iliac and femoropopliteal obstructions. Wr klin Wschr 1986; 98: 33-40
• 24 Schneider E, Griintzig AR, Bollinger A. Long-term results after PTA in 882 consecutive patients with iliac and femoropopliteal obstructions. VASA 1982; 11: 322-326
• 25 Marker LA, Ross R, Slichter S, Scott C. Homocystine - induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741
• 26 Lipton MJ, Doherty PW, Goodwin DA, Bushberg GT, Prager R, Meares CF. Evaluation of catheter thrombogenicity in vivo with Indium-labelled platelets. Radiology 1980; 135: 191-194
• 27 Blattler W, Cappius G, Haeberli A, Foullon N, Roth FJ. Throm-binemia during percutaneous transluminal angioplasty of chronic femoral artery occlusions. VASA 1986; 15: 379-386
• 28 Sixma JJ, Bouma BN. Physiology and biochemistry of the haemostatic system. In: Van de Loo J, Prentice CRM, Beller FK. (eds) The thromboembolic disorders. Schattauer, Stuttgart; New York: 1983: 3-43
• 29 Heptinstall S, Mitchell J RA. Antiplatelet therapy. Mode of action and clinical value. In: Van de Loo J, Prentice CRM, Beller FK. (eds) The thromboembolic disorders. Schattauer, Stuttgart; New York: 1983: 129-157
• 30 Friedmann RJ, Burns ER. Role of platelets in the proliferation response of the injured artery. In: Spaet Th. (ed). Progress in Hemostasis and Thrombosis. Vol 4 Orlando; Fla, Grune & Stratton: 1978: 249
• 31 Weiss HJ, Tschopp ThB, Baumgartner HR. Impaired interaction (adhesion-aggregation) of platelets with the subendothelium in storage-pool disease and after aspirin ingestion. N Engl J Med 1975; 293: 619-623
• 32 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood vessel walls. N Engl J Med 1979; 300: 1142-1147
• 33 Majerus PhW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72: 1521-1525
• 34 Hanson StR, Harker LA. Bjornsson Th D. Effects of plateletmodifying drugs on arterial thromboembolism in baboons. J Clin Invest 1985; 75: 1591-1599